Core Viewpoint - MAIA Biotechnology, Inc. has successfully closed a public offering of 20 million shares at $1.50 per share, raising a total of $30 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 20,000,000 shares priced at $1.50 each, resulting in gross proceeds of $30 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 3,000,000 shares at the same price to cover any overallotments [1]. - The offering was structured as a common stock-only investment with no warrant coverage, led by healthcare-dedicated investors [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for conducting clinical trials, working capital, and general corporate purposes [2]. Group 3: Company Background - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [7].

Core Viewpoint - MAIA Biotechnology, Inc. has announced a public offering of 20 million shares at a price of $1.50 per share, aiming to raise $30 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering consists of 20,000,000 shares priced at $1.50 each, with expected gross proceeds of $30 million before expenses [1]. - The underwriters have a 45-day option to purchase an additional 3,000,000 shares at the same price to cover over-allotments [1]. - The offering is structured as a common stock-only investment with no warrant coverage [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for conducting clinical trials, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on August 23, 2023 [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC [4]. Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [7].

Core Viewpoint - MAIA Biotechnology, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to use the proceeds for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes shares of common stock and pre-funded warrants, with a 30-day option for underwriters to purchase additional shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Management and Use of Proceeds - Konik Capital Partners LLC is acting as the sole book-running manager for the offering [2]. - The net proceeds from the offering will be utilized for conducting clinical trials and for working capital and general corporate purposes [2]. Group 3: Regulatory Information - The securities are being offered under a "shelf" registration statement on Form S-3, which was filed with the SEC and declared effective in August 2023 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on its website [4].

Group 1 - MAIA Biotechnology, Inc. has entered into definitive agreements for the purchase and sale of 1,233,488 shares of common stock at a price of $1.224 per share in a private placement to accredited investors and a Company director [1] - Each share is offered with a warrant to purchase one additional share at an exercise price of $1.36, with the warrants exercisable six months after issuance and valid for three years [1] - The private placement is expected to close on or about December 18, 2025, subject to customary closing conditions [1] Group 2 - The gross proceeds from the offering are expected to be approximately $1.51 million before offering expenses [2] - The net proceeds will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for working capital [2] Group 3 - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws [3] - The warrants and underlying shares may not be offered or sold in the United States except under an effective registration statement or applicable exemption [3] Group 4 - MAIA is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5]

Core Insights - MAIA Biotechnology, Inc. is demonstrating strong insider confidence through recent share purchases by CEO Dr. Vlad Vitoc and board members, acquiring approximately 182,445 shares between November 21 and 28, 2025, signaling belief in the long-term value of the ateganosine platform [1][2][3] Group 1: Insider Activity - The recent insider buying reflects a unified stance from MAIA's leadership, showcasing confidence in the company's strategy and the clinical evidence supporting ateganosine as a potential therapeutic pathway for advanced non-small cell lung cancer (NSCLC) [2][3] - Directors and Officers currently hold 4,480,120 shares, representing 12.95% of the company, indicating significant insider ownership and commitment [3] Group 2: Clinical Development - Ateganosine, MAIA's lead program, is in mid- to late-stage clinical development and has shown encouraging results, enhancing both internal and external confidence in its potential as a first-in-class cancer therapy targeting telomerase-positive cancer cells [2][4] - The company's approach is positioned as a meaningful new therapeutic pathway for patients with advanced NSCLC, highlighting the innovative nature of its drug development strategy [2][4]

Core Insights - MAIA Biotechnology, Inc. announced that its CEO and certain board members purchased approximately 182,445 shares of the company's common stock at an average price of $1.06 between November 21 and 28, 2025 [1][2] Company Overview - MAIA is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, specifically its lead program, ateganosine (THIO), which targets telomerase-positive cancer cells in non-small cell lung cancer (NSCLC) patients [4] Recent Developments - Vlad Vitoc, M.D., the Chairman and CEO, purchased 94,300 shares at an average price of $1.08, while other board members Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares at an average price of $1.04 [2] - The company reported a 38% response rate and an overall survival of 17.8 months in its Phase 2 THIO-101 clinical trial, indicating the potential of ateganosine to improve patient outcomes [3] Management Confidence - The management expressed confidence in the ongoing clinical development of ateganosine, highlighting its potential to become a new standard of care for patients with non-small cell lung cancer [3] - Board members emphasized the strategic focus and scientific momentum of the company, suggesting it is well-positioned to deliver significant value for shareholders in the future [3]

Core Viewpoint - MAIA Biotechnology, Inc. has announced a private placement of 603,769 shares of common stock at a price of $1.22 per share, along with warrants for additional shares, aimed at raising approximately $736,600 to fund clinical trials and working capital [1][2]. Group 1: Private Placement Details - The private placement involves the sale of 603,769 shares at $1.22 each, with each share accompanied by a warrant to purchase one additional share at an exercise price of $1.52 [1]. - The warrants will be exercisable six months after issuance and will have a term of three years [1]. - The expected gross proceeds from the offering are approximately $736,600, before expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital [2]. Group 3: Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5].

Core Insights - MAIA Biotechnology has authorized the allocation of up to 90% of its liquid assets in cryptocurrencies, specifically Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC) [1][2] - The company aims to diversify its investment portfolio through a new digital asset treasury strategy, focusing on high-quality cryptocurrency tokens to minimize risk while seeking strong returns [3] Group 1: Digital Asset Strategy - The Board of Directors has approved a strategy to hold a significant portion of liquid assets in cryptocurrencies, with corporate officers authorized to manage these transactions [2] - MAIA's CEO emphasized a disciplined approach to investing in cryptocurrencies, targeting only the highest-quality tokens to enhance shareholder value while maintaining adequate working capital [3] Group 2: Company Overview - MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO) for treating NSCLC patients [4]

Core Viewpoint - MAIA Biotechnology, Inc. has announced a private placement of 1,733,766 shares of common stock at a price of $1.30 per share, along with warrants for additional shares, aiming to raise approximately $2.25 million to fund clinical trials and working capital [1][2]. Group 1: Private Placement Details - The private placement involves the sale of 1,733,766 shares at $1.30 each, with each share accompanied by a warrant to purchase one additional share at an exercise price of $1.57 [1]. - The warrants are exercisable six months after issuance and have a term of three years [1]. - The expected gross proceeds from the offering are approximately $2.25 million, prior to offering expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for general working capital [2]. Group 3: Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5].

Core Insights - MAIA Biotechnology, Inc. has reported positive efficacy data from its Phase 2 clinical trial, THIO-101, which evaluates ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients who have failed multiple standard therapies [1][2] Group 1: Efficacy Data - The Phase 2 trial THIO-101 shows a progression-free survival (PFS) of 5.6 months, which is more than double the standard of care PFS of 2.5 months [2][6] - The estimated median overall survival (OS) is reported at 17.8 months, with a 95% confidence interval lower bound of 12.5 months [6] Group 2: Drug Mechanism and Development - Ateganosine is a first-in-class investigational telomere-targeting agent that induces telomerase-dependent telomeric DNA modification and selective cancer cell death [3] - The drug activates both innate and adaptive immune responses, leading to significant tumor regression in advanced cancer models [3] Group 3: Clinical Trial Design - THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition [4] - The trial has two primary objectives: to evaluate the safety and tolerability of ateganosine and to assess its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [4] Group 4: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with ateganosine being its lead program aimed at treating NSCLC patients with telomerase-positive cancer cells [7]